Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Evacetrapib in Healthy Subjects
NCT02271425Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evacetrapib in hypercholesterolemia and cardiovascular disease (CVD), sponsored by Eli Lilly and Company. Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity at 168 hours. Started Oct 2014; status: completed.
02
Drugs
evacetrapib
03
Conditions
hypercholesterolemiacardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT02271425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271425.